AAAAAA

   
Results: 1-9 |
Results: 9
Determination of etoposide in human plasma and leukemic cells by high-performance liquid chromatography with electrochemical detection
Authors: Zhou, R Frostvik-Stolt, M Liliemark, E
Citation: R. Zhou et al., Determination of etoposide in human plasma and leukemic cells by high-performance liquid chromatography with electrochemical detection, J CHROMAT B, 757(1), 2001, pp. 135-141
In vitro topo II-DNA complex accumulation and cytotoxicity of etoposide inleukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia
Authors: Wang, YY Zhou, R Liliemark, J Gruber, A Lindemalm, S Albertioni, F Liliemark, E
Citation: Yy. Wang et al., In vitro topo II-DNA complex accumulation and cytotoxicity of etoposide inleukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia, LEUK RES, 25(2), 2001, pp. 133-140
Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide
Authors: Lotfi, K Mansson, E Chandra, J Wang, YY Xu, DW Knaust, E Spasokoukotskaja, T Liliemark, E Eriksson, S Albertioni, F
Citation: K. Lotfi et al., Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide, BR J HAEM, 113(2), 2001, pp. 339-346
Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children
Authors: Eksborg, S Soderhall, S Frostvik-Stolt, M Lindberg, A Liliemark, E
Citation: S. Eksborg et al., Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children, ANTI-CANC D, 11(4), 2000, pp. 237-241
P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein-positive acute myeloid leukemia
Authors: Tidefelt, U Liliemark, J Gruber, A Liliemark, E Sundman-Engberg, B Juliusson, G Stenke, L Elmhorn-Rosenborg, A Mollgard, L Lehman, S Xu, D Covelli, A Gustavsson, B Paul, C
Citation: U. Tidefelt et al., P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein-positive acute myeloid leukemia, J CL ONCOL, 18(9), 2000, pp. 1837-1844
Topoisomerase II-mediated alterations of K562 drug resistant sublines
Authors: Zhou, R Wang, Y Gruber, A Larsson, R Castano-Velez, E Liliemark, E
Citation: R. Zhou et al., Topoisomerase II-mediated alterations of K562 drug resistant sublines, MED ONCOL, 16(3), 1999, pp. 191-198
In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells
Authors: Wang, YY Eksborg, S Lewensohn, R Lindberg, A Liliemark, E
Citation: Yy. Wang et al., In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells, ANTI-CANC D, 10(10), 1999, pp. 921-928
Characterization of drug-resistant cell lines by comparative genomic hybridization
Authors: Carlson, KM Gruber, A Liliemark, E Larsson, R Nordenskjold, M
Citation: Km. Carlson et al., Characterization of drug-resistant cell lines by comparative genomic hybridization, CANC GENET, 111(1), 1999, pp. 32-36
Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL
Authors: Zhou, R Vitols, S Gruber, A Liliemark, J Wang, Y Liliemark, E
Citation: R. Zhou et al., Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL, BR J HAEM, 105(2), 1999, pp. 420-427
Risultati: 1-9 |